172 related articles for article (PubMed ID: 18487279)
1. Structural requirements of anti-GD1a antibodies determine their target specificity.
Lopez PH; Zhang G; Bianchet MA; Schnaar RL; Sheikh KA
Brain; 2008 Jul; 131(Pt 7):1926-39. PubMed ID: 18487279
[TBL] [Abstract][Full Text] [Related]
2. Localization of major gangliosides in the PNS: implications for immune neuropathies.
Gong Y; Tagawa Y; Lunn MP; Laroy W; Heffer-Lauc M; Li CY; Griffin JW; Schnaar RL; Sheikh KA
Brain; 2002 Nov; 125(Pt 11):2491-506. PubMed ID: 12390975
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of GD1a ganglioside sensitizes motor nerve terminals to anti-GD1a antibody-mediated injury in a model of acute motor axonal neuropathy.
Goodfellow JA; Bowes T; Sheikh K; Odaka M; Halstead SK; Humphreys PD; Wagner ER; Yuki N; Furukawa K; Furukawa K; Plomp JJ; Willison HJ
J Neurosci; 2005 Feb; 25(7):1620-8. PubMed ID: 15716397
[TBL] [Abstract][Full Text] [Related]
4. GalNAc-GD1a in human peripheral nerve: target sites of anti-ganglioside antibody.
Kaida K; Kusunoki S; Kamakura K; Motoyoshi K; Kanazawa I
Neurology; 2003 Aug; 61(4):465-70. PubMed ID: 12939418
[TBL] [Abstract][Full Text] [Related]
5. T cell response in acute motor axonal neuropathy.
Cencioni MT; Notturno F; Caporale CM; Creati B; Prencipe V; Battistini L; Uncini A
Int J Immunopathol Pharmacol; 2009; 22(4):1043-50. PubMed ID: 20074468
[TBL] [Abstract][Full Text] [Related]
6. Association of antibodies to ganglioside complexes and conduction blocks in axonal Guillain-Barré syndrome presenting as acute motor conduction block neuropathy.
Créange A; Shahrizaila N; Salhi H; Lefaucheur JP; Yuki N
J Peripher Nerv Syst; 2014 Jun; 19(2):115-20. PubMed ID: 24750296
[TBL] [Abstract][Full Text] [Related]
7. Temporal profile of anti-ganglioside antibodies and their relation to clinical parameters and treatment in Guillain-Barré syndrome.
Press R; Matá S; Lolli F; Zhu J; Andersson T; Link H
J Neurol Sci; 2001 Sep; 190(1-2):41-7. PubMed ID: 11574105
[TBL] [Abstract][Full Text] [Related]
8. Ganglioside mimicry as a cause of Guillain-Barré syndrome.
Komagamine T; Yuki N
CNS Neurol Disord Drug Targets; 2006 Aug; 5(4):391-400. PubMed ID: 16918391
[TBL] [Abstract][Full Text] [Related]
9. Fine specificities of anti-LM1 IgG antibodies in Guillain-Barré syndrome.
Susuki K; Yuki N; Hirata K; Kuwabara S
J Neurol Sci; 2002 Mar; 195(2):145-8. PubMed ID: 11897245
[TBL] [Abstract][Full Text] [Related]
10. Patterns and serial changes in electrodiagnostic abnormalities of axonal Guillain-Barré syndrome.
Hiraga A; Kuwabara S; Ogawara K; Misawa S; Kanesaka T; Koga M; Yuki N; Hattori T; Mori M
Neurology; 2005 Mar; 64(5):856-60. PubMed ID: 15753422
[TBL] [Abstract][Full Text] [Related]
11. Detection of anti-ganglioside antibodies in Guillain-Barré syndrome and its variants by the agglutination assay.
Alaedini A; Briani C; Wirguin I; Siciliano G; D'Avino C; Latov N
J Neurol Sci; 2002 Apr; 196(1-2):41-4. PubMed ID: 11959155
[TBL] [Abstract][Full Text] [Related]
12. Identification of gangliosides recognized by IgG anti-GalNAc-GD1a antibodies in bovine spinal motor neurons and motor nerves.
Yoshino H; Ariga T; Suzuki A; Yu RK; Miyatake T
Brain Res; 2008 Aug; 1227():216-20. PubMed ID: 18598683
[TBL] [Abstract][Full Text] [Related]
13. Axonal Guillain-Barré syndrome: relation to anti-ganglioside antibodies and Campylobacter jejuni infection in Japan.
Ogawara K; Kuwabara S; Mori M; Hattori T; Koga M; Yuki N
Ann Neurol; 2000 Oct; 48(4):624-31. PubMed ID: 11026446
[TBL] [Abstract][Full Text] [Related]
14. Antiganglioside antibodies are associated with axonal Guillain-Barré syndrome: a Japanese-Italian collaborative study.
Sekiguchi Y; Uncini A; Yuki N; Misawa S; Notturno F; Nasu S; Kanai K; Noto Y; Fujimaki Y; Shibuya K; Ohmori S; Sato Y; Kuwabara S
J Neurol Neurosurg Psychiatry; 2012 Jan; 83(1):23-8. PubMed ID: 22010183
[TBL] [Abstract][Full Text] [Related]
15. Acute motor axonal neuropathy and acute motor-sensory axonal neuropathy share a common immunological profile.
Yuki N; Kuwabara S; Koga M; Hirata K
J Neurol Sci; 1999 Oct; 168(2):121-6. PubMed ID: 10526194
[TBL] [Abstract][Full Text] [Related]
16. GM1/GalNAc-GD1a complex: a target for pure motor Guillain-Barre syndrome.
Kaida K; Sonoo M; Ogawa G; Kamakura K; Ueda-Sada M; Arita M; Motoyoshi K; Kusunoki S
Neurology; 2008 Nov; 71(21):1683-90. PubMed ID: 19015484
[TBL] [Abstract][Full Text] [Related]
17. Anti-ganglioside antibodies alter presynaptic release and calcium influx.
Buchwald B; Zhang G; Vogt-Eisele AK; Zhang W; Ahangari R; Griffin JW; Hatt H; Toyka KV; Sheikh KA
Neurobiol Dis; 2007 Oct; 28(1):113-21. PubMed ID: 17720506
[TBL] [Abstract][Full Text] [Related]
18. Rapidly progressive, predominantly motor Guillain-Barré syndrome with anti-GalNAc-GD1a antibodies.
Ang CW; Yuki N; Jacobs BC; Koga M; Van Doorn PA; Schmitz PI; Van Der Meché FG
Neurology; 1999 Dec; 53(9):2122-7. PubMed ID: 10599792
[TBL] [Abstract][Full Text] [Related]
19. Recognition characteristics of monoclonal antibodies that are cross-reactive with gangliosides and lipooligosaccharide from Campylobacter jejuni strains associated with Guillain-Barré and Fisher syndromes.
Houliston RS; Yuki N; Hirama T; Khieu NH; Brisson JR; Gilbert M; Jarrell HC
Biochemistry; 2007 Jan; 46(1):36-44. PubMed ID: 17198373
[TBL] [Abstract][Full Text] [Related]
20. An antibody to the GM1/GalNAc-GD1a complex correlates with development of pure motor Guillain-Barré syndrome with reversible conduction failure.
Ogawa G; Kaida K; Kuwahara M; Kimura F; Kamakura K; Kusunoki S
J Neuroimmunol; 2013 Jan; 254(1-2):141-5. PubMed ID: 23000056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
